Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Studien
Brg2.5
Gerstengras – Forschung
Überwiegend Mechanismus / Beobachtung
6 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Gerstengras sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 2002–2026 mit einer typischen Studiengröße von 36 Teilnehmenden.
Basierend auf 5 Studien · 36 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Glucose & metabolicEine kleine T2DM-Studie zeigte eine verringerte LDL-Oxidation; Tierdaten zeigen ein verbessertes Lipidprofil — jedoch sind metabolische Endpunkte beim Menschen nicht belegt · Unbekannt
Zu wenige bewertete Studien1 Studie
Stetige Forschung
1 Studie in den letzten 5 Jahren
200220142026
1Übersicht2026
Einfach gesagt: In conclusion, young barley preparations represent a biologically plausible functional plant food ingredient with preliminary clinical support, pending confirmation from adequately powered, standardised randomised controlled trials.
Rzeski W et al. · Molecules (Basel, Switzerland) (2026)
Agronomic variables including fertilization strategy and soil composition represent additional, underappreciated sources of phytochemical variability and safety concern.
Overall, the current evidence supports the biological plausibility of young barley as a functional plant food; yet, the clinical data remain preliminary.
Future research should prioritize preparation standardization, dose-response characterization, and agronomic transparency to strengthen translational reliability.
Einfach gesagt: Conclusion This review underscores the therapeutic potential of barley and its components in chronic disease management, highlighting the need for well-designed clinical trials to translate these findings into effective interventions.
Ali A, Ullah Z, Ullah R, Kazi M. · Heliyon (2024)
Results The finding suggests that humans digest barley starch more slowly than wheat and rice, which benefits chronic disease management.
Barley's high-molecular-weight β-glucan high content acts as a prebiotic, promotes gut health through microbiome modulation and short-chain fatty acid production, potentially preventing colon cancer and boosting immunity.
Conclusion This review underscores the therapeutic potential of barley and its components in chronic disease management, highlighting the need for well-designed clinical trials to translate these findings into effective interventions.
Einfach gesagt: Supplementation with young barley leaf extract helped scavenge oxygen free radicals and inhibit LDL oxidation, with the effect on small dense LDL strongest when combined with vitamins C and E.
36 type 2 diabetic patients received 15g barley leaf extract, vitamins C+E, or both daily for 4 weeks (three active arms, no placebo, not randomized)
Blood chemiluminescence (free-radical) levels fell in all groups; barley leaf preserved LDL vitamin E and increased oxidation lag time
Combined barley leaf + vitamins C/E most effectively inhibited small dense LDL oxidation; small, short, single trial
4Tierstudie2019
Einfach gesagt: In high-fat-diet rats, barley grass juice reduced body weight and BMI and improved lipid profile and liver markers, with histology showing reduced atherosclerosis.
Einfach gesagt: Barley grass extract inhibited breast and prostate cancer cell viability and induced apoptosis by raising intracellular reactive oxygen species in vitro.
Woo SM, Kwon SC, Ko SG, Cho SG. · Biomed Rep (2017)
Barley grass extract reduced viability of breast and prostate cancer cell lines (MTT assay)
Induced apoptosis via increased intracellular ROS, blocked by the antioxidant N-acetyl-cysteine
In-vitro cell study only; no relevance established for whole-body human outcomes